Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 321

1.

Connective tissue growth factor (CTGF/CCN2) in serum is an indicator of fibrogenic progression and malignant transformation in patients with chronic hepatitis B infection.

Gressner OA, Fang M, Li H, Lu LG, Gressner AM, Gao CF.

Clin Chim Acta. 2013 Jun 5;421:126-31. doi: 10.1016/j.cca.2013.02.029. Epub 2013 Mar 15.

PMID:
23501329
2.

Connective tissue growth factor reacts as an IL-6/STAT3-regulated hepatic negative acute phase protein.

Gressner OA, Peredniene I, Gressner AM.

World J Gastroenterol. 2011 Jan 14;17(2):151-63. doi: 10.3748/wjg.v17.i2.151.

3.

Increased serum xylosyltransferase activity in patients with liver fibrosis.

Kuhn J, Gressner OA, Götting C, Gressner AM, Kleesiek K.

Clin Chim Acta. 2009 Nov;409(1-2):123-6. doi: 10.1016/j.cca.2009.09.013. Epub 2009 Sep 13.

PMID:
19755118
4.

Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.

Gressner OA, Beer N, Jodlowski A, Gressner AM.

Clin Chim Acta. 2009 Nov;409(1-2):90-5. doi: 10.1016/j.cca.2009.09.005. Epub 2009 Sep 10.

PMID:
19748500
5.

BMP-7 as antagonist of organ fibrosis.

Weiskirchen R, Meurer SK, Gressner OA, Herrmann J, Borkham-Kamphorst E, Gressner AM.

Front Biosci (Landmark Ed). 2009 Jun 1;14:4992-5012. Review.

PMID:
19482601
6.

Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey.

Gressner AM, Gao CF, Gressner OA.

World J Gastroenterol. 2009 May 28;15(20):2433-40.

7.

Inverse association between serum concentrations of actin-free vitamin D-binding protein and the histopathological extent of fibrogenic liver disease or hepatocellular carcinoma.

Gressner OA, Gao C, Siluschek M, Kim P, Gressner AM.

Eur J Gastroenterol Hepatol. 2009 Sep;21(9):990-5. doi: 10.1097/MEG.0b013e3283293769.

PMID:
19322100
8.

Intraperitoneal application of caffeine prevents D-galactosamine-induced hepatic expression of connective tissue growth factor (CTGF/CCN2) in the rat.

Gressner OA, Siluschek M, Lahme B, Gressner AM.

J Hepatol. 2009 May;50(5):1053-5. doi: 10.1016/j.jhep.2009.02.001. Epub 2009 Mar 3. No abstract available. Retraction in: J Hepatol. 2010 Sep;53(3):590.

PMID:
19321219
9.

Connective tissue growth factor is a Smad2 regulated amplifier of transforming growth factor beta actions in hepatocytes--but without modulating bone morphogenetic protein 7 signaling.

Gressner OA, Lahme B, Siluschek M, Rehbein K, Weiskirchen R, Gressner AM.

Hepatology. 2009 Jun;49(6):2021-30. doi: 10.1002/hep.22850.

PMID:
19309720
10.

Identification of paraxanthine as the most potent caffeine-derived inhibitor of connective tissue growth factor expression in liver parenchymal cells.

Gressner OA, Lahme B, Siluschek M, Gressner AM.

Liver Int. 2009 Jul;29(6):886-97. doi: 10.1111/j.1478-3231.2009.01987.x. Epub 2009 Mar 5.

PMID:
19291178
11.

Secreted cysteine-rich FGF receptor derives from posttranslational processing by furin-like prohormone convertases.

Antoine M, Köhl R, Tag CG, Gressner AM, Hellerbrand C, Kiefer P.

Biochem Biophys Res Commun. 2009 May 1;382(2):359-64. doi: 10.1016/j.bbrc.2009.03.026. Epub 2009 Mar 11.

PMID:
19285038
12.

Evaluation of serum percent trisialotransferrin as potential predictive biomarker of hepatocellular dedifferentiation in chronic liver disease.

Gressner OA, Jafari S, Erkens M, Gao C, Stanzel S, Gressner AM.

Clin Chim Acta. 2009 May;403(1-2):188-93. doi: 10.1016/j.cca.2009.02.017. Epub 2009 Mar 10.

PMID:
19281805
13.

Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis.

Kovalenko E, Tacke F, Gressner OA, Zimmermann HW, Lahme B, Janetzko A, Wiederholt T, Berg T, Müller T, Trautwein C, Gressner AM, Weiskirchen R.

J Viral Hepat. 2009 Sep;16(9):612-20. doi: 10.1111/j.1365-2893.2009.01110.x. Epub 2009 Feb 20.

PMID:
19243500
14.

Expression of E-selectin ligand-1 (CFR/ESL-1) on hepatic stellate cells: implications for leukocyte extravasation and liver metastasis.

Antoine M, Tag CG, Gressner AM, Hellerbrand C, Kiefer P.

Oncol Rep. 2009 Feb;21(2):357-62.

PMID:
19148508
15.

Elevated concentrations of 15-deoxy-Delta12,14-prostaglandin J2 in chronic liver disease propose therapeutic trials with peroxisome proliferator activated receptor gamma-inducing drugs.

Gressner OA, Gao C, Rehbein K, Lahme B, Siluschek M, Berg T, Müller T, Gressner AM.

Liver Int. 2009 May;29(5):730-5. doi: 10.1111/j.1478-3231.2008.01895.x. Epub 2008 Oct 15.

PMID:
19018984
16.

Altered factor VII activating protease expression in murine hepatic fibrosis and its influence on hepatic stellate cells.

Roderfeld M, Weiskirchen R, Atanasova S, Gressner AM, Preissner KT, Roeb E, Kanse SM.

Liver Int. 2009 May;29(5):686-91. doi: 10.1111/j.1478-3231.2008.01897.x. Epub 2008 Oct 15.

PMID:
19018983
17.

Questioning the role of actinfree Gc-Globulin as actin scavenger in neurodegenerative central nervous system disease: relationship to S-100B levels and blood-brain barrier function.

Gressner OA, Schifflers MC, Kim P, Heuts L, Lahme B, Gressner AM.

Clin Chim Acta. 2009 Feb;400(1-2):86-90. doi: 10.1016/j.cca.2008.10.015. Epub 2008 Oct 30.

PMID:
19000909
18.

Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases.

Gressner OA, Gressner AM.

Liver Int. 2008 Sep;28(8):1065-79. doi: 10.1111/j.1478-3231.2008.01826.x. Review.

PMID:
18783549
19.

Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury.

Borkham-Kamphorst E, Kovalenko E, van Roeyen CR, Gassler N, Bomble M, Ostendorf T, Floege J, Gressner AM, Weiskirchen R.

Lab Invest. 2008 Oct;88(10):1090-100. doi: 10.1038/labinvest.2008.71. Epub 2008 Jul 28.

20.

Maternal factor V Leiden mutation is associated with HELLP syndrome in Caucasian women.

Muetze S, Leeners B, Ortlepp JR, Kuse S, Tag CG, Weiskirchen R, Gressner AM, Rudnik-Schoeneborn S, Zerres K, Rath W.

Acta Obstet Gynecol Scand. 2008;87(6):635-42. doi: 10.1080/00016340802112740.

21.

Transforming growth factor beta 1 gene variants increase transcription and are associated with liver cirrhosis in Chinese.

Wang H, Zhao YP, Gao CF, Ji Q, Gressner AM, Yang ZX, Weiskirchen R.

Cytokine. 2008 Jul;43(1):20-5. doi: 10.1016/j.cyto.2008.04.013. Epub 2008 Jun 10.

PMID:
18547814
22.

Changing the pathogenetic roadmap of liver fibrosis? Where did it start; where will it go?

Gressner OA, Rizk MS, Kovalenko E, Weiskirchen R, Gressner AM.

J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 1):1024-35. doi: 10.1111/j.1440-1746.2008.05345.x. Epub 2008 May 26. Review.

PMID:
18505415
23.

Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways.

Gressner OA, Lahme B, Rehbein K, Siluschek M, Weiskirchen R, Gressner AM.

J Hepatol. 2008 Nov;49(5):758-67. doi: 10.1016/j.jhep.2008.03.029. Epub 2008 Apr 30.

PMID:
18486259
24.

Intracrine signalling of activin A in hepatocytes upregulates connective tissue growth factor (CTGF/CCN2) expression.

Gressner OA, Lahme B, Siluschek M, Rehbein K, Weiskirchen R, Gressner AM.

Liver Int. 2008 Nov;28(9):1207-16. doi: 10.1111/j.1478-3231.2008.01729.x. Epub 2008 Apr 7.

PMID:
18397232
25.

Evaluation of a novel reverse-hybridization StripAssay for typing DNA variants useful in diagnosis of adult-type hypolactasia.

Tag CG, Oberkanins C, Kriegshäuser G, Ingram CJ, Swallow DM, Gressner AM, Ledochowski M, Weiskirchen R.

Clin Chim Acta. 2008 Jun;392(1-2):58-62. doi: 10.1016/j.cca.2008.03.006. Epub 2008 Mar 18.

PMID:
18396155
26.

[Potential novel biomarkers for monitoring the fibrogenic process in livers].

Gao CF, Gressner AM, Chen C.

Zhonghua Gan Zang Bing Za Zhi. 2008 Mar;16(3):173-4. Chinese. No abstract available.

PMID:
18364071
27.

Zinc supplementation in the elderly reduces spontaneous inflammatory cytokine release and restores T cell functions.

Kahmann L, Uciechowski P, Warmuth S, Plümäkers B, Gressner AM, Malavolta M, Mocchegiani E, Rink L.

Rejuvenation Res. 2008 Feb;11(1):227-37. doi: 10.1089/rej.2007.0613.

PMID:
18279033
28.

Activation of TGF-beta within cultured hepatocytes and in liver injury leads to intracrine signaling with expression of connective tissue growth factor.

Gressner OA, Lahme B, Siluschek M, Rehbein K, Herrmann J, Weiskirchen R, Gressner AM.

J Cell Mol Med. 2008 Dec;12(6B):2717-30. doi: 10.1111/j.1582-4934.2008.00260.x. Epub 2008 Feb 4.

29.
30.

Hepatic stellate cells display a functional vascular smooth muscle cell phenotype in a three-dimensional co-culture model with endothelial cells.

Wirz W, Antoine M, Tag CG, Gressner AM, Korff T, Hellerbrand C, Kiefer P.

Differentiation. 2008 Sep;76(7):784-94. doi: 10.1111/j.1432-0436.2007.00260.x. Epub 2008 Jan 3.

PMID:
18177423
31.

Evaluation of hepatotropic targeting properties of allogenic and xenogenic erythrocyte ghosts in normal and liver-injured rats.

Gressner OA, Lahme B, Koch M, Gressner AM.

Liver Int. 2008 Feb;28(2):220-32. Epub 2007 Dec 6.

PMID:
18069973
32.

TGF-beta up-regulates serum response factor in activated hepatic stellate cells.

Herrmann J, Haas U, Gressner AM, Weiskirchen R.

Biochim Biophys Acta. 2007 Dec;1772(11-12):1250-7. Epub 2007 Nov 4.

33.

The interleukin-6 (IL6)-174 G/C promoter genotype is associated with the presence of septic shock and the ex vivo secretion of IL6.

Tischendorf JJ, Yagmur E, Scholten D, Vidacek D, Koch A, Winograd R, Gressner AM, Trautwein C, Wasmuth HE, Lammert F.

Int J Immunogenet. 2007 Dec;34(6):413-8.

PMID:
18001296
34.

Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality.

Gressner OA, Weiskirchen R, Gressner AM.

J Cell Mol Med. 2007 Sep-Oct;11(5):1031-51. Review.

35.

Disruption of the latent transforming growth factor-beta binding protein-1 gene causes alteration in facial structure and influences TGF-beta bioavailability.

Drews F, Knöbel S, Moser M, Muhlack KG, Mohren S, Stoll C, Bosio A, Gressner AM, Weiskirchen R.

Biochim Biophys Acta. 2008 Jan;1783(1):34-48. Epub 2007 Aug 29.

36.

Immortal hepatic stellate cell lines: useful tools to study hepatic stellate cell biology and function?

Herrmann J, Gressner AM, Weiskirchen R.

J Cell Mol Med. 2007 Jul-Aug;11(4):704-22. Review.

37.

Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma.

Yagmur E, Rizk M, Stanzel S, Hellerbrand C, Lammert F, Trautwein C, Wasmuth HE, Gressner AM.

Eur J Gastroenterol Hepatol. 2007 Sep;19(9):755-61.

PMID:
17700260
38.

Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options.

Gressner OA, Weiskirchen R, Gressner AM.

Comp Hepatol. 2007 Jul 30;6:7.

39.

Expression and function of fibroblast growth factor (FGF) 9 in hepatic stellate cells and its role in toxic liver injury.

Antoine M, Wirz W, Tag CG, Gressner AM, Marvituna M, Wycislo M, Hellerbrand C, Kiefer P.

Biochem Biophys Res Commun. 2007 Sep 21;361(2):335-41. Epub 2007 Jul 24.

PMID:
17662249
40.

Pitfalls in LightCycler diagnosis of the single-nucleotide polymorphism 13.9 kb upstream of the lactase gene that is associated with adult-type hypolactasia.

Weiskirchen R, Tag CG, Mengsteab S, Gressner AM, Ingram CJ, Swallow DM.

Clin Chim Acta. 2007 Sep;384(1-2):93-8. Epub 2007 Jun 16.

PMID:
17651714
41.

Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes.

Gressner OA, Lahme B, Demirci I, Gressner AM, Weiskirchen R.

J Hepatol. 2007 Nov;47(5):699-710. Epub 2007 Jun 26.

PMID:
17629588
42.

Glucocorticoids activate TGF-beta induced PAI-1 and CTGF expression in rat hepatocytes.

Wickert L, Chatain N, Kruschinsky K, Gressner AM.

Comp Hepatol. 2007 May 2;6:5.

43.

Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests.

Gressner OA, Weiskirchen R, Gressner AM.

Clin Chim Acta. 2007 Jun;381(2):107-13. Epub 2007 Feb 27. Review.

PMID:
17399697
44.

Pro-fibrogenic potential of PDGF-D in liver fibrosis.

Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, Floege J, Gressner AM, Weiskirchen R.

J Hepatol. 2007 Jun;46(6):1064-74. Epub 2007 Feb 23.

PMID:
17397961
45.

Endoglin differentially modulates antagonistic transforming growth factor-beta1 and BMP-7 signaling.

Scherner O, Meurer SK, Tihaa L, Gressner AM, Weiskirchen R.

J Biol Chem. 2007 May 11;282(19):13934-43. Epub 2007 Mar 21.

46.

Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4.

Yagmur E, Weiskirchen R, Gressner AM, Trautwein C, Tacke F.

Diabetes Care. 2007 May;30(5):1168-72. Epub 2007 Mar 2.

PMID:
17337499
47.

Elevated apoptosis-associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation.

Yagmur E, Trautwein C, Leers MP, Gressner AM, Tacke F.

Clin Biochem. 2007 Jun;40(9-10):651-5. Epub 2007 Jan 17.

PMID:
17306787
48.

High prevalence of increased trisialotransferrin concentrations in patients with anorexia nervosa: implications for determination of carbohydrate-deficient transferrin.

Arndt T, Erkens M, Holtkamp K, Keller T, Gressner AM.

Clin Chim Acta. 2007 Apr;379(1-2):150-3. Epub 2007 Jan 23.

PMID:
17291470
49.

Ito cells are liver-resident antigen-presenting cells for activating T cell responses.

Winau F, Hegasy G, Weiskirchen R, Weber S, Cassan C, Sieling PA, Modlin RL, Liblau RS, Gressner AM, Kaufmann SH.

Immunity. 2007 Jan;26(1):117-29.

50.

Loss of TGF-beta dependent growth control during HSC transdifferentiation.

Purps O, Lahme B, Gressner AM, Meindl-Beinker NM, Dooley S.

Biochem Biophys Res Commun. 2007 Feb 16;353(3):841-7. Epub 2006 Dec 26.

PMID:
17204247

Supplemental Content

Loading ...
Support Center